Get the Stockscreener App
8.055
0.62%
-0.045
Novavax Inc stock is traded at $8.055, with a volume of 1.19M.
It is down -0.62% in the last 24 hours and down -1.59% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$8.10
Open:
$8.03
24h Volume:
1.19M
Relative Volume:
0.29
Market Cap:
$1.32B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-3.5175
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
+2.29%
1M Performance:
-1.59%
6M Performance:
-40.85%
1Y Performance:
+53.33%
1-Day Range:
$8.0224
$8.50
1-Week Range:
$7.655
$8.50
52-Week Range:
$3.81
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.055 | 1.32B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.15 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.99 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.18 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.18 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.47 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Canada cancels Novavax Covid vaccine purchase - New Vision
Canada cancels purchase of Covid-19 vaccine from Novavax - БГНЕС
Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates - Simply Wall St
Head to Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Novavax (NASDAQ:NVAX) - Defense World
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax Announces Board Changes and Strategic Shift - TipRanks
Need To Know: Analysts Just Made A Substantial Cut To Their Novavax, Inc. (NASDAQ:NVAX) Estimates - Yahoo Finance
Federal government cancels deal with US company to make COVID-19 vaccine in Montreal - Montreal Gazette
Novavax faces contract termination with Canadian government By Investing.com - Investing.com South Africa
Novavax falls as Canada terminates COVID-19 vaccine purchase deal - TradingView
Canada Cancels Novavax Covid Vaccine Purchase - Barron's
Novavax Faces Contract Termination with Canadian Government - TipRanks
Novavax faces termination of Covid-19 vaccine purchase deal with Canada due to missed regulatory approval deadlines, SEC filing shows - Marketscreener.com
Novavax: retirement of the Chairman of the Board of Directors -March 11, 2025 at 09:55 am EDT - Marketscreener.com
Novavax faces contract termination with Canadian government - Investing.com
Novavax Chair James Young Retires; Margaret McGlynn Named Successor -March 11, 2025 at 09:02 am EDT - Marketscreener.com
Novavax appoints new chair as James Young retires - Investing.com India
Novavax Announces Changes to Board of Directors - PR Newswire
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Novavax, Inc. to Host Earnings Call - ACCESS Newswire
Novavax, Inc. (NASDAQ:NVAX) Shares Bought by Oppenheimer & Co. Inc. - Defense World
Novavax (NasdaqGS:NVAX) Shares Rise 11% Following Q4 2024 Earnings Improvement - Yahoo Finance
Novavax (NVAX) Predicts Profitability by 2027 Despite Recent Stock Drop - Markets Insider
B. Riley Issues Pessimistic Estimate for Novavax Earnings - Defense World
Novavax, Inc. (NASDAQ:NVAX) Shares Bought by Rhumbline Advisers - Defense World
(NVAX) Investment Report - news.stocktradersdaily.com
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - MSN
Novavax to Present Strategic Plans at Health Conference - TipRanks
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates - MSN
Stock Market Insights: Snap And Novavax Trends - Evrim Ağacı
Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership - MSN
Novavax, Inc. (NASDAQ:NVAX) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating (NASDAQ:NVAX) - Seeking Alpha
Novavax, Inc. (NASDAQ:NVAX) Q4 2024 Earnings Call Transcript - Insider Monkey
1 Biotech Stock to Buy in 2025, and 1 to Avoid - MSN
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus.com
Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic P - GuruFocus.com
Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... - Yahoo Finance
Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... By GuruFocus - Investing.com Canada
Novavax: Q4 Earnings Snapshot - Huron Daily Tribune
Novavax Reports 2024 Earnings and Strategic Shift - TipRanks
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership - MSN
Novavax initiated with a Buy at BTIG - TipRanks
Novavax Earnings Call: Strategic Moves and Challenges - TipRanks
Novavax Looks To Right Its Ship Amid Revenue Slump - Citeline News & Insights
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Novavax Stock: Narrowing Losses Drive Market Confidence - sharewise
Novavax to Participate in Upcoming March Investor Conferences - Quantisnow
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '25 |
Option Exercise |
0.00 |
12,223 |
0 |
75,155 |
| Trizzino John | President and COO |
Mar 01 '25 |
Option Exercise |
0.00 |
48,000 |
0 |
76,310 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
4,000 |
0 |
33,187 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '25 |
Option Exercise |
0.00 |
58,667 |
0 |
91,269 |
| Jacobs John C | President and CEO |
Mar 01 '25 |
Option Exercise |
0.00 |
83,334 |
0 |
175,183 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
59,600 |
0 |
73,825 |
| Jacobs John C | President and CEO |
Jan 23 '25 |
Option Exercise |
0.00 |
83,196 |
0 |
130,722 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Dec 31 '24 |
Option Exercise |
0.00 |
35,000 |
0 |
49,508 |
| Rodgers Richard J | Director |
Oct 29 '24 |
Option Exercise |
0.00 |
3,800 |
0 |
14,270 |
| King Rachel K. | Director |
Dec 13 '24 |
Sale |
9.02 |
4,150 |
37,435 |
14,770 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):